Free Trial

hVIVO (HVO) Competitors

hVIVO logo
GBX 8.15 -0.15 (-1.81%)
As of 08:36 AM Eastern

HVO vs. PRTC, VRP, FARN, AVCT, ARIX, CIR, BVXP, 4BB, TILS, and VSN

Should you be buying hVIVO stock or one of its competitors? The main competitors of hVIVO include PureTech Health (PRTC), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Avacta Group (AVCT), Arix Bioscience (ARIX), Circassia Group (CIR), Bioventix (BVXP), 4basebio (4BB), Tiziana Life Sciences (TILS), and Verseon (VSN). These companies are all part of the "biotechnology" industry.

hVIVO vs. Its Competitors

hVIVO (LON:HVO) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

hVIVO has a net margin of 25.96% compared to PureTech Health's net margin of -17,620.94%. hVIVO's return on equity of 47.93% beat PureTech Health's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO25.96% 47.93% 11.97%
PureTech Health -17,620.94%-21.15%-13.39%

In the previous week, PureTech Health had 32 more articles in the media than hVIVO. MarketBeat recorded 40 mentions for PureTech Health and 8 mentions for hVIVO. hVIVO's average media sentiment score of 0.91 beat PureTech Health's score of 0.29 indicating that hVIVO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
hVIVO
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
PureTech Health
8 Very Positive mention(s)
6 Positive mention(s)
23 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

hVIVO presently has a consensus price target of GBX 23, suggesting a potential upside of 182.21%. PureTech Health has a consensus price target of GBX 455, suggesting a potential upside of 255.85%. Given PureTech Health's higher possible upside, analysts plainly believe PureTech Health is more favorable than hVIVO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
PureTech Health
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

4.6% of hVIVO shares are held by institutional investors. Comparatively, 53.1% of PureTech Health shares are held by institutional investors. 4.4% of hVIVO shares are held by insiders. Comparatively, 13.1% of PureTech Health shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

hVIVO has higher revenue and earnings than PureTech Health. hVIVO is trading at a lower price-to-earnings ratio than PureTech Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£62.73M0.89£17.84M£0.02525.81
PureTech Health£6.17M50.12-£91.86M£0.17752.14

hVIVO has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.02, indicating that its stock price is 2% more volatile than the S&P 500.

Summary

PureTech Health beats hVIVO on 8 of the 15 factors compared between the two stocks.

Get hVIVO News Delivered to You Automatically

Sign up to receive the latest news and ratings for HVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HVO vs. The Competition

MetrichVIVOBiotechnology IndustryMedical SectorLON Exchange
Market Cap£56.01M£231.09M£5.76B£2.58B
Dividend Yield2.02%3.78%5.53%5.33%
P/E Ratio525.8131.9076.255,422.61
Price / Sales0.894,690.26470.4997,659.15
Price / Cash4.9413.1937.4627.93
Price / Book1.47127.1813.358.86
Net Income£17.84M-£90.99M£3.29B£5.89B
7 Day Performance-16.42%-0.06%1.83%0.96%
1 Month Performance-18.50%18.23%3.98%2.92%
1 Year Performance-72.61%680.37%74.39%177.77%

hVIVO Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HVO
hVIVO
2.1873 of 5 stars
GBX 8.15
-1.8%
GBX 23
+182.2%
-70.8%£56.01M£62.73M525.81N/ANews Coverage
Earnings Report
Analyst Forecast
PRTC
PureTech Health
2.2239 of 5 stars
GBX 107.20
-1.1%
GBX 455
+324.4%
-11.7%£259.09M£6.17M630.59300Insider Trade
High Trading Volume
VRP
Verona Pharma plc (VRP.L)
N/AN/AN/AN/A£228MN/A-1.6822Gap Up
FARN
Faron Pharmaceuticals Oy
N/AGBX 187.90
+0.2%
N/A-8.4%£210.36MN/A-695.9334Gap Down
AVCT
Avacta Group
N/AGBX 52.35
-0.3%
N/A-8.8%£210.33M£113K-341.26120
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down
BVXP
Bioventix
N/AGBX 2,466.50
+0.7%
N/A-37.9%£128.88M£13.66M1,665.2012News Coverage
High Trading Volume
4BB
4basebio
1.2908 of 5 stars
GBX 831
-1.1%
GBX 1,600
+92.5%
-46.4%£128.68M£933K-884.04101
TILS
Tiziana Life Sciences
N/AN/AN/AN/A£113.85M-£3.60M-3.5911News Coverage
VSN
Verseon
N/AN/AN/AN/A£112.24MN/A-5.17N/AGap Up

Related Companies and Tools


This page (LON:HVO) was last updated on 9/24/2025 by MarketBeat.com Staff
From Our Partners